Drug Trial Radar · NCT07348042
Study of RGL-270 Single Drug and Combined With Adebelimab in Patients in Patients at High Risk of Recurrence After Radical Treatment of Malignant Solid Tumors
Last checked: Nov 19, 2026Latest source record: Jan 16, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
198
Planned (sponsor's estimate)
Start
Sep 7, 2025
Primary completion
Mar 31, 2027
Study completion Dec 31, 2027
Sponsor
- Lead sponsor
- Xian-Jun YuAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- First posted
- Jan 16, 2026
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Non randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years, up to 75 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This study is a phase I clinical trial of multi-center, open label, dose increase and dose expansion. It aims to evaluate the safety, tolerance, PK characteristics, immunogenicity and initial efficacy of personalized new antigen mRNA vaccine RGL-270 (hereinafter referred to as RGL-270) alone and combined with adebelizumab in patients with high risk of recurrence of malignant solid tumors after radical treatment.
Conditions
- Tumor, Solid
Interventions
RGL-270 InjectionDrug
Repeated medication, increase the dose
Adebelimab InjectionDrug
Repeated medication, the dose is maintained
Primary outcomes
What the sponsor says the trial is designed to measure.
- Maximum tolerated dose (MTD) of RGL-270 monotherapy or the maximum dose (MAD) when MTD is not reached, and determine the recommended extended dose (RDE) for RGL-270Time frame: Day 1 to week 24 after RGL-270 administration
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Fudan University Shanghai Cancer Center
Shanghai, China · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.